/C O R R E C T I O N -- Eli Lilly and Company/

ConferenceP-tau217amyloid-targeting treatmentNeutral

AI Analysis

Summary

Eli Lilly announced it will present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment. This is a correction notice regarding a previously issued news release.

Importance:3/10

Sentiment:

0.00

Alzheimer's diseasebiomarkerconference presentationAAIC 2026diagnostictherapeutic

Related Companies

$LLY

Read the original article

Published by PR Newswire Pharma on July 9, 2026 5:16 PM

Read Original